JPRN-UMIN000008953
Completed
Phase 2
Phase II Study of De-intensified Treatment (radiation alone) for Human Papilloma Virus-Associated Oropharyngeal Cancer - Radiotherapy for HPV Associated Oropharyngeal Cancer
Osaka University Graduate School of Medicine, Dept. of Otorhinolaryngology-Head and Neck Surgery0 sites39 target enrollmentSeptember 20, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- resectable human papilloma virus associated locally advanced oropharyngeal cancer
- Sponsor
- Osaka University Graduate School of Medicine, Dept. of Otorhinolaryngology-Head and Neck Surgery
- Enrollment
- 39
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. previously irradiated the same field as currently scheduled 2\. presence of active second primary cancer. heterochronic second primary cancers with no evidence of disease more than 36 months and superficial second primary cancers are allowed. 3\. presence of active infectious disease or presence of fever above 38 centidegree 4\. cases judged as inappropriate 5\. T4 or/and N3
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Phase II study of intensive treatment for newly diagnosed elderly acute myeloid leukemia, fitted for standard chemotherapy like younger adults, by Japan Adult Leukemia Study Group (JALSG-GML219)JPRN-jRCTs041190088Ito Yoshikazu128
Active, not recruiting
Phase 1
A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapyAdvanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapyTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-000775-20-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest40
Active, not recruiting
Not Applicable
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion. - STP-LYM-01-V01EUCTR2009-014641-88-DEMedizinische Fakultaet der Technischen Universitaet Muenchen
Active, not recruiting
Not Applicable
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemiarelapsed or refractory Chronic Lymphocytic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2006-006694-24-DEFresenius Biotech GmbH
Completed
Phase 2
Phase II study of remission induction therapy with bendamustine and rituximab combination (BR) therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.(BRiZ2012 protocol)follicular lymphomaJPRN-UMIN000008793Society of Lymphoma Treatment in Japan (SoLTJ)28